Maria Dioverti Prono, MD
Infectious Disease · Baltimore, MDNPI 1194957159
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Paratek Pharmaceuticals, Inc. at 37.7% of the total. Reporting peaked in 2019 at $4,766 and has fallen 62.0% since, to $1,812 in 2025.
Across 13 payments — averaging $972.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Paratek Pharmaceuticals, Inc.$5K
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- Roche Diagnostics Corporation$3K
- Regeneron$2K
- E.r. Squibb & Sons, L.L.C.$500
- AstraZeneca$34
- plus $11 from 1 others
Across 25 payments — averaging $12,830 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$238K
- Merck$83K
What the payments were for
- Consulting fees$6,06248%
- Speaking & faculty fees$6,02248%
- Travel & lodging$3883%
- Food & beverage$1621%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Paratek Pharmaceuticals, Inc. | 5 | $4,766 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $2,877 |
| Roche Diagnostics Corporation | 1 | $2,645 |
| Regeneron | 2 | $1,812 |
| E.r. Squibb & Sons, L.L.C. | 1 | $500 |
| AstraZeneca | 1 | $34 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUZYRA$4,672
How this compares
$12,645 in reported general payments places this provider in the 85th percentile of 289 infectious disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Posaconazole | 11 | $12,791 |
| CeftriaxoneCeftriaxone Sodium | 13 | $247 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $91 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Baltimore
- Robert RedfieldBaltimore$779K
- Luciana BorioBaltimore$671K
- Mark SulkowskiBaltimore$240K
- Jonathan ZenilmanBaltimore$202K
- Robert EdelmanBaltimore$125K
- Kjell WibergBaltimore$113K
- Christine DurandBaltimore$53K
- Myron LevineBaltimore$51K
- Robert BollingerBaltimore$50K
- Richard BergBaltimore$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.